Therefore, it could be supported that VEGF-A and ICAM-1 variants might be significant predictive biomarkers of great clinical importance.
← all excerpts
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
1
—
—